References
- Otto P, de Villiers MM. Poly(amidoamine) dendrimers as a pharmaceutical excipient. Are we there yet? J Pharm Sci. 2018;107:75–83.
- Franiak-Pietryga I, Maciejewskic H, Ostrowska K, et al. Dendrimer-based nanoparticles for potential personalized therapy inchronic lymphocytic leukemia: targeting the BCR-signaling pathway. Int J Biol Macromol. 2016;88:156–161.
- Arima H, Arizono M, Higashi T, et al. Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with a-cyclodextrin as DNA carriers to tumor cells. Cancer Gene Ther. 2012;19:358–366.
- Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev. 2008;60:1037–1055.
- Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2012;64:102–115.
- Somani S, Dufès C. Applications of dendrimers for brain delivery and cancer therapy. Nanomedicine (Lond). 2014;9:2403–2414.
- Mendes PL, Pan J, Torchilin PV. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules. 2017;22:1401–1423.
- Abbasi E, Aval FS, Akbarzadeh A, et al. Dendrimers: synthesis, applications, and properties. Nanoscale Res Lett. 2014;9:247–257.
- Kundu GC, Schullek JR, Wilson IB. The alkylating properties of chlorambucil. Pharmacol Biochem Behav. 1994;49:621–624.
- Montserrat E, Rozman C. Chronic lymphocytic leukaemia treatment. Blood Rev. 1993;7:164–175.
- Pedersen JP, Christensen SM, Ruysschaert T, et al. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs. J Med Chem. 2009;52:3408–3415.
- Iglesias-Guerra F, Candela IJ, Blanco E, et al. Alkylating agents from sugars: synthesis of chlorambucil derivatives carried by chiral glycosyl glycerols derived from h-glucosamine. Chirality. 2002;14:199–203.
- Ghose T, Norvell ST, Guclu A, et al. Immunochemotherapy of cancer with chlorambucil-carrying antibody. Br Med J. 1972;3:495–499.
- Bielawski K, Bielawska A, Muszyńska A, et al. Cytotoxic activity of G3 PAMAM-NH2 dendrimer–chlorambucil conjugate in human breast cancer cells. Environ Toxicol Pharmacol. 2011;32:364–372.
- Pedro-Hernández LD, Martínez-Klimova E, et al. Synthesis, characterization and nanomedical applications of conjugates between resorcinarene-dendrimers and ibuprofen. Nanomaterials. 2017;7:163–173.
- Pedro-Hernández LD, Martínez-Klimova E, Martínez-Klimov ME, et al. Anticancer activity of resorcinarene-PAMAM-dendrimers conjugates of flutamide. Anti-Cancer Agents Med Chem. 2018;18:993-1000.
- Ramírez-Arroniz JC, Martínez-Klimova E, Pedro-Hernández LD, et al. Water soluble porphyrin-melphalan conjugates and their anticancer activity. Drug Dev Ind Pharm. 2018;44:1342–1349.
- Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. *J Natl Cancer Inst. 1991;83:757–766.